The sensitivity of this blood-based test for colorectal cancer was 83.1%, whereas reported sensitivity of other noninvasive screening tests ranges from 67.3% (95% CI, 57.1 to 76.5) with FIT 15 and ...

More information: Mohamed Adil et al, Preeclampsia risk prediction from prenatal cell-free DNA screening, Nature Medicine (2025). DOI: 10.1038/s41591-025-03509-w ...

Secondary Source New England Journal of Medicine Source Reference: Vora NL "Cell-free DNA screening and maternal cancer" N Engl J Med 2024; DOI: 10.1056/NEJMe2412259.

Aldevron’s Alchemy™ is an exclusive cell-free DNA technology which cuts research grade linear DNA manufacturing time by over 50 percent, accelerating mRNA development projects with cleaner ...

More information: Hua Bao et al, Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics, Nature Medicine (2025). DOI: 10.1038/s41591-025-03735-2 ...

PURPOSEUsing the prostate, lung, colorectal, and ovarian (PLCO) Cancer Screening Trial samples, we identified cell-free DNA (cfDNA) candidate biomarkers bearing the epigenetic mark ...

Reference Chung DC, Gray II DM, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390 (11):973-983. doi:10.1056/NEJMoa2304714 ...

The usefulness of the cell-free DNA blood test (cf-bDNA) can vary based on the reasons for using the method of screening for colorectal cancer (CRC). According to a new study published in Annals ...

For the new cell-free DNA testing, a small amount of a person's blood is tested for a large number of cancers. A positive test could indicate that the person has a certain type of cancer in theory ...

More information: Mohamed Adil et al, Preeclampsia risk prediction from prenatal cell-free DNA screening, Nature Medicine (2025). DOI: 10.1038/s41591-025-03509-w ...